Over 1150 Total Lots Up For Auction at Three Locations - WI 07/09, NJ Cleansweep 07/10, CA 07/11

Dr. David Wong

Professor recognized for contributions to PET and Theranostics
September 12, 2018
Molecular Imaging PET

David attributes his achievements to his wife, Mary and two sons – Daniel and Michael who remind him daily what the things truly important in life are.

In recognition of his contributions to the field of nuclear medicine, Dr. David Wong was featured in the 26th through 29th editions of Who's Who in the World.

stats
DOTmed text ad

You don’t have to invest heavily in CT technology to achieve your Coronary CTA goals

Fast-moving cardiac structures have a big impact on imaging. Fujifilm’s SCENARIA View premium performance CT brings solutions to address motion in Coronary CTA while delivering unique dose saving and workflow increasing benefits.

stats
SOURCE Marquis Who's Who

Back to HCB News

You Must Be Logged In To Post A Comment

 

advertisement

Molecular Imaging Homepage

GE HealthCare highlights new AI-powered tools for theranostics at SNMMI
LesionID Pro automates preprocessing for whole-body tumor burden analysis
New PET technique enables simultaneous imaging of three radiotracers
'Triplexed' PET combines a pure positron emitter with two prompt-gamma plus positron emitters in one imaging session
FDA expands use of GE HealthCare’s Vizamyl PET imaging agent in Alzheimer’s care
Can now be used to monitor treatment response, and more
Ratio Therapeutics secures isotope supply deal with Nusano for radiopharmaceutical development
Nusano has proprietary platform for generating over 40 isotopes for medical and industrial applications
GE HealthCare and Stanford Medicine partner on total body PET/CT
Designed to support multi-organ dynamic imaging, ultralow-dose protocols, and greater throughput
Siemens Healthineers, Mass General launch theranostics research center
Researchers will use Biograph Vision Quadra and Biograph Trinion PET/CT scanners
Clarity signs commercial supply deal with SpectronRx for Cu-64 SAR-bisPSMA
Will manufacture the isotope and finished agent, with capacity up to 400,000 patient-ready doses annually
Philochem licenses prostate cancer radiopharmaceutical to Bristol Myers in deal worth up to $1.35 billion
Partnership will focus on the development and commercialization of OncoACP3
IONETIX expands Michigan radiopharmaceutical operations with $26 million investment
Poised to bring 53 new jobs to Lansing
SNMMI gathers during a banner year for nuclear medicine
Discussing the upcoming meeting with president-elect Dr. Jean-Luc Urbain